Pharsight

Kerendia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8436180 BAYER HLTHCARE Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
Apr, 2029

(4 years from now)

USRE49826 BAYER HLTHCARE Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient
Jul, 2035

(11 years from now)

Kerendia is owned by Bayer Hlthcare.

Kerendia contains Finerenone.

Kerendia has a total of 2 drug patents out of which 0 drug patents have expired.

Kerendia was authorised for market use on 09 July, 2021.

Kerendia is available in tablet;oral dosage forms.

Drug patent challenges can be filed against Kerendia from 09 July, 2025.

The generics of Kerendia are possible to be released after 29 July, 2035.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 09, 2026
M(M-279) Sep 01, 2025

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using FINERENONE ingredient

NCE-1 date: 09 July, 2025

Market Authorisation Date: 09 July, 2021

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

KERENDIA family patents

Family Patents